NexGard Combo, a monthly broad-spectrum parasiticide for cats, has earned the approval of the U.S. Food and Drug Administration.
The manufacturer, Boehringer Ingelheim Animal Health, reported that veterinary clinics may order NexGard Combo (esafoxolaner, eprinomectin and praziquantel topical solution) starting in May.
The product, which the company described as “first of its kind,” is indicated to protect cats against fleas, ticks, heartworm disease and intestinal parasites, including tapeworms. Esafoxolaner is formulated to kill fleas and ticks, eprinomectin to prevent heartworm disease and treat and control roundworms and hookworms, and praziquantel for the treatment and control of tapeworms.
“By combining three active ingredients in a one-and-done monthly application, NexGard Combo makes it easy for cat owners to protect their pets,” Boehringer Ingelheim stated, “To further enable compliance, veterinarians can prescribe three-dose and six-dose presentations to best support the needs of their feline patients.”
The parasiticide may be used with cats at least 8 weeks old and weighing 1.8 pounds or more.